Linked Life Data

16428498

Source:http://linkedlifedata.com/resource/pubmed/id/16428498

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-1-23
pubmed:abstractText
The purpose of this study was to evaluate the long-term tumor response after phase IIb clinical study and the safety of percutaneous holmium-166 ((166)Ho)/chitosan complex injection (PHI) therapy for small hepatocellular carcinoma as a local ablative treatment. (166)Ho is a radioactive isotope derived from natural holmium-165. We developed a (166)Ho/chitosan complex (Milican, Dong Wha Pharmaceutical Co., Seoul, Korea) using chitosan as a vehicle to retain the radioactive material within the tumor.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
543-8
pubmed:dateRevised
2010-3-23
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma.
pubmed:affiliation
Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei Liver Cancer Study Group, Yonsei University College of Medicine, 134 Shinchoin-dong, Seodaemoon-gu, Seoul, Korea 120-752.
pubmed:publicationType
Journal Article, Clinical Trial, Phase II